Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 PE Ratio (TTM) is 20.37 as of Aug. 28, 2026, which is 76% below its 10-year median of 84.29. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 433 Healthcare Providers & Services companies, NeuPath Health ranks better than 52.42% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-28), NeuPath Health's share price is
C$0.55.
NeuPath Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was C$0.03. Therefore, NeuPath Health's PE Ratio (TTM) for today is 20.37.
Good Sign:
NeuPath Health Inc stock PE Ratio (=20.74) is close to 3-year low of 20.74.
The historical rank and industry rank for NeuPath Health's PE Ratio (TTM) or its related term are showing as below:
TSXV:NPTH'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 20.37 Med: 84.29 Max: 100
Current: 20.37
During the past 7 years, the highest PE Ratio (TTM) of NeuPath Health was 100.00. The lowest was 20.37. And the median was 84.29.
TSXV:NPTH's PE Ratio (TTM) is ranked better than 52.42% of 433
companies
in the Healthcare Providers & Services industry
Industry Median: 21.79
vs TSXV:NPTH: 20.37
During the past 7 years, NeuPath Health's highest 3-Year average EPS without NRI Growth Rate was 67.50% per year. The lowest was 11.00% per year. And the median was 64.10% per year.
NeuPath Health's EPS (Basic) for the
three
months ended in Jun. 2026 was C$0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was C$0.03.
NeuPath Health (TSXV:NPTH) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
NeuPath Health PE Ratio (TTM) Related Terms
NeuPath Health PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for NeuPath Health's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NPTH vs HCA, THC, DVA: PE Ratio (TTM) Comparison
For the Medical Care Facilities subindustry, NeuPath Health's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health PE Ratio (TTM) vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where NeuPath Health's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
NeuPath Health's PE Ratio (TTM) for today is calculated as
NeuPath Health's Share Price of today is C$0.55.
NeuPath Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
NeuPath Health (TSXV:NPTH) has a PE Ratio (TTM) of 20.37 as of Aug. 28, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on NeuPath Health and its competitors. This is 76% below median its historical median of 84.29. Over the past decade, NeuPath Health's PE Ratio (TTM) has ranged from 20.37 to 100.00. According to the industry distribution chart, NeuPath Health ranks #206 out of 433 companies in the Healthcare Providers & Services industry, placing it in the top 47.6%.
Is NeuPath Health's PE Ratio (TTM) too high?
NeuPath Health's current PE Ratio (TTM) of 20.37 is 76% below median its 10-year median of 84.29. Over the past 10 years, this metric has ranged from a low of 20.37 to a high of 100.00. The Healthcare Providers & Services industry median PE Ratio (TTM) is 21.79. NeuPath Health's value of 20.37 is 6.5% below this industry median. Based on the distribution chart, NeuPath Health ranks #206 out of 433 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's PE Ratio (TTM) compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #206 out of 433 companies for PE Ratio (TTM). This puts NeuPath Health in the upper half of its industry. The industry median PE Ratio (TTM) is 21.79. NeuPath Health's value of 20.37 is 6.5% below this benchmark. Historically, NeuPath Health's own PE Ratio (TTM) has ranged from 20.37 to 100.00 over the past decade. While the company's 10-year median is 84.29 vs. the industry median of 21.79, NeuPath Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Healthcare Providers & Services company?
The median PE Ratio (TTM) among Healthcare Providers & Services companies is 21.79, based on 433 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current PE Ratio (TTM) of 20.37 is 6.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median PE Ratio (TTM) is 21.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current PE Ratio (TTM) is 20.37, which is 76% below median its own 10-year median of 84.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current PE Ratio (TTM) is 20.37, which is 76% below median its 10-year median of 84.29 and 6.5% below the Healthcare Providers & Services industry median of 21.79. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current PE Ratio (TTM) is 20.37 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
PE Ratio (TTM): 20.37 (76% below median its 10-year median of 84.29)
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
Industry Position: 6.5% below the Healthcare Providers & Services median (#206 of 433)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
